🇫🇷 France Country × Condition
advanced solid tumor Clinical Trials in France
Active clinical trials for advanced solid tumor with research sites in France. All data sourced live from ClinicalTrials.gov — updated daily.
Active Trials: 4 // Recruiting: 4 Phases: Phase 1, Phase 2 // Updated: Daily
Total Trials
4
Recruiting Now
4
Country
🇫🇷 France
Active Trials in France (4)
NCT06533059 Phase 1
Recruiting
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
Enrollment
110 pts
Country
🇫🇷 France
Alterome Therapeutics, Inc.
View Trial → NCT03767075 Phase 2
Recruiting
A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)
Enrollment
1,000 pts
Country
🇫🇷 France
Vall d'Hebron Institute of Oncology
View Trial → NCT04585750 Phase 1, Phase 2
Recruiting
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Enrollment
300 pts
Country
🇫🇷 France
PMV Pharmaceuticals, Inc
View Trial → NCT06154291 Phase 1, Phase 2
Recruiting
FIH XON7 in Advanced/Metastatic Solid Tumors
Enrollment
255 pts
Country
🇫🇷 France
Xenothera SAS
View Trial → Frequently Asked Questions
How many advanced solid tumor clinical trials are active in France?
There are currently 4 active clinical trials for advanced solid tumor with sites in France, of which 4 are actively recruiting patients.
How can I join a advanced solid tumor clinical trial in France?
To join a advanced solid tumor clinical trial in France, select a recruiting trial below and check the eligibility criteria. Contact the trial's principal investigator or the listed site in France directly. All trials listed here are sourced from ClinicalTrials.gov, the official U.S. registry of clinical studies.
What phases are advanced solid tumor trials in France?
Active advanced solid tumor trials in France span Phase 1, Phase 2, Phase 1, Phase 2. Phase I trials test safety, Phase II test efficacy, and Phase III compare against standard treatments in larger patient populations.